Mark Erlander, PhD | Chief Scientific Officer
Mark Erlander, Ph.D., has been our Chief Scientific Officer since March 2013 and has been instrumental in successfully transitioning the Company from cancer-focused diagnostics to being at the forefront of precision cancer therapeutics.
Dr. Erlander has more than 20 years of experience directing drug discovery efforts and developing precision cancer diagnostics and his expertise in precision cancer medicine is focused on leveraging the intersection of targeted therapies and with molecular diagnostic biomarkers. Prior to joining Trovagene, Dr. Erlander was Chief Scientific Officer at bioTheranostics (a bioMerieux company), which was previously AviaraDx and acquired by bioMerieux, from September 2008 to February 2013. As CSO, he led R&D, Medical & Scientific Affairs and clinical laboratory operations or the development of proprietary predictive tests in oncology to inform therapy decisions. Dr. Erlander entered therapeutics as a Group Leader and then Research Fellow in drug discovery at Johnson & Johnson.
At J&J, Dr. Erlander led both efforts in drug discovery and the use of genomic technologies to identify new drug targets. Previous to this, he was an Assistant Professor at The Scripps Research Institute where he also received his post-doctoral training. Dr. Erlander is an accomplished researcher in oncology therapeutics, diagnostics and genomic technologies with 44 issued U.S. patents and over 50 pending applications. He has co-authored over 90 scientific publications. Dr. Erlander holds a BS degree in Biochemistry from the University of California, Davis; an MS degree in Biochemistry from Iowa State University; and a Ph.D. in Neuroscience from the University of California, Los Angeles.